PGNX News and Press, Progenics Pharmaceuticals Inc. From 12/22/19

NEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call to review the top line re...

NEW YORK, NY / ACCESSWIRE / December 13, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Audentes Therapeutics, Inc ( BOLD ) relat...

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Anixter International Inc. (NYSE: AXE) The investigation concerns whether Anixter and its board of directors violated the federal securit...

NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting PyL (¹⁸F-DCFPyL)...

Progenics Pharmaceutics (NASDAQ: PGNX ) appoints board member David Mims as interim CEO , while the search continues for a permanent head of the company. More news on: Progenics Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced its Board of Directors has appointed David W. Mims as interim...

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced th...

Progenics Stockholders Consent to Removal of CEO Mark Baker, Dr. David Scheinberg and Nicole Williams and Election of All Five Velan Nominees – Gérard Ber, Eric Ende, Ann MacDougall, Heinz Mäusli and David Mims Velan Capital, L.P. (together with the other members of it...

Progenics Pharmaceuticals (NASDAQ: PGNX ): Q3 GAAP EPS of -$0.22 beats by $0.04 . More news on: Progenics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical Therapeutics AZEDRA Commercial Dosing Progresses in U.S. as New Technology Add-On Payment Became Effective Octo...